secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021658
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q1 revenue $47.5M, net loss $4.1M; Fanapt bipolar approval, PONVORY launch in Q3
--------------------------------------------------------------------------------

- Net loss $4.1M (diluted EPS -$0.07) vs net income $3.3M ($0.06) in Q1 2023; revenue $47.5M, -24% YoY.
- Cash increased $5.9M to $394.1M; Fanapt approved for acute bipolar I disorder, launch Q3 2024.
- PONVORY commercial launch in multiple sclerosis expected Q3 2024; tradipitant NDA for gastroparesis under FDA review with PDUFA Sept 18, 2024.
- Milsaperidone NDA for schizophrenia and bipolar expected early-2025; tradipitant motion sickness Phase III results Q2 2024.
- No FY 2024 guidance given due to HETLIOZ generic competition and upcoming launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/0001628280-24-021658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828024021658/vnda-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer